Brii Biosciences
Brii Biosciences is a US-listed (HKEX) clinical-stage biopharmaceutical company developing therapeutic candidates for infectious diseases — primarily chronic hepatitis B, HIV, COVID-19, and multi-drug resistant bacterial infections — and central nervous system disorders, bringing in-licensed and acquired global assets into the China market through state-distribution partnerships.
- Company typePublic
- Founded2018
- HeadquartersBeijing, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Brii Biosciences does
Brii Biosciences is a clinical-stage biopharmaceutical company founded in 2018 with a dual US-China operating model, headquartered in Durham, North Carolina with R&D and commercial operations in Beijing and Shanghai. The company is publicly listed on the Hong Kong Stock Exchange (ticker BRIBF, IPO July 2021) and has raised approximately $415 million across its founding financing and 2021 Series C round. Brii develops therapeutic candidates in two therapeutic areas: infectious diseases, anchored by a chronic hepatitis B functional cure program built on siRNA (BRII-835/Elebsiran, licensed from Vir Biotechnology), an HBV immunotherapeutic (BRII-179/VBI-2601, IP acquired from VBI Vaccines in December 2024), and a broadly neutralizing HBV monoclonal antibody (BRII-877/VIR-3434); and central nervous system disorders, including a long-acting therapy for postpartum depression and major depressive disorder (BRII-296).
The company's revenue model is hybrid: licensing royalties and milestone payments from out-licensing arrangements (e.g., soralimixin licensed to Joincare Group in Greater China in July 2025, and various co-development collaborations with Vir, VBI, WuXi Biologics, Qpex Biopharma, AN2 Therapeutics, and Artizan Biosciences), product sales of its one approved asset — amubarvimab/romlusevimab, the first COVID-19 neutralizing antibody combination approved by China's NMPA in December 2021 and commercially launched in July 2022 — and strategic distribution arrangements with Sinopharm and China Resources Pharmaceutical Commercial Group for China market access. The company operates a sales-led GTM leveraging state-controlled Chinese distributors rather than its own sales force, and engages global pharmaceutical partners for asset sourcing and co-development.
Customer concentration is anchored on a small number of strategic partners and government-linked distributors; with one approved product facing an evolving COVID therapeutics market and multiple pipeline assets still in Phase 2 trials, Brii is structurally a pre-commercialization company with cash runway of US$276.1 million as of December 2025 and FY2025 net loss reduced to RMB 224.1 million from RMB 512.4 million in 2024. Recent strategic emphasis has shifted toward portfolio rationalization (acquiring full BRII-179 IP, divesting Qpex equity, out-licensing non-core assets), AI-augmented drug discovery via the December 2025 OpenBench collaboration, and discovery capability buildout through new Shanghai wet lab operations.
Brii Biosciences firmographics
Firmographics- Name
- Brii Biosciences
- Legal name
- 腾盛博药医药技术（北京）有限公司 (Brii Biosciences Pharmaceutical Technology (Beijing) Co., Ltd.)
- Website
- https://briibio.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Brii Biosciences is a US-listed (HKEX) clinical-stage biopharmaceutical company developing therapeutic candidates for infectious diseases — primarily chronic hepatitis B, HIV, COVID-19, and multi-drug resistant bacterial infections — and central nervous system disorders, bringing in-licensed and acquired global assets into the China market through state-distribution partnerships.
- Ownership category
- akta.pro rank
Brii Biosciences industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
- akta.pro secondary industries
- Tuberculosis & Mycobacterial Diseases (HLAKAGAH), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Brii Biosciences is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
Brii Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Licensing Agreements: Revenue primarily generated from licensing agreements for drug candidates in Greater China territory, including VIR-2218 from Vir Biotechnology and BRII-179 from VBI Vaccines
- Product Sales: Revenue from commercialized products such as the amubarvimab/romlusevimab combination therapy for COVID-19 approved in China
- Strategic Partnerships: Revenue generation through strategic out-licensing agreements such as the soralimixin agreement with Joincare Group in Greater China
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Brii Biosciences product offering
Product offeringCore offering
Brii Biosciences is a multi-national biopharmaceutical company that develops, licenses, and commercializes innovative therapeutic candidates for infectious diseases (chronic hepatitis B, HIV, COVID-19), CNS disorders (postpartum depression, major depressive disorder), and multi-drug resistant bacterial infections, primarily for the Greater China market. The company functions as a bridge between global pharmaceutical innovation (via partnerships with Vir Biotechnology, VBI Vaccines, WuXi Biologics, Qpex Biopharma) and Chinese patients, leveraging its licensed platform technologies (siRNA ESC+, monoclonal antibodies, bispecific antibodies) and partnerships with Sinopharm and China Resources Pharmaceutical Commercial Group for commercialization.
Product overview
Brii Biosciences is a multi-national biopharmaceutical company developing first-in-class and different-in-class treatments for infectious diseases and CNS diseases. The company operates a pipeline of therapeutic candidates including BRII-179 (VBI-2601), a novel HBV immunotherapeutic; BRII-835 (VIR-2218/Elebsiran), an siRNA therapeutic for chronic hepatitis B; BRII-196/BRII-198 (Amubarvimab/Romlusevimab), a COVID-19 neutralizing antibody combination; BRII-296 for postpartum depression; BRII-732 and BRII-778 for HIV; and antibiotics BRII-636, BRII-672, and BRII-693 developed with Qpex Biopharma. The company focuses on areas with high unmet medical needs, social stigmas, and limited treatment options, with operations in China and the United States.
Differentiator
Problem solved
Functional benefit
Products and services
- Amubarvimab/Romlusevimab (BRII-196/BRII-198) Non-competing SARS-CoV-2 neutralizing antibody combination therapy derived from convalescent COVID-19 patients. Engineered to reduce risk of antibody-dependent enhancement and prolong plasma half-life for durable treatment effect. Received NMPA approval in China in December 2021 and included in China's COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition) in March 2022.
- BRII-835 (VIR-2218 / Elebsiran) Subcutaneously administered HBV-targeting siRNA (small interfering RNA) with potential to stimulate effective immune response and direct antiviral activity against HBV. First siRNA in clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity. Received CDE Breakthrough Therapy Designation from China's Center for Drug Evaluation.
- BRII-179 (VBI-2601) Novel recombinant protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI's prophylactic 3-antigen HBV vaccine candidate. Designed to target enhanced B-cell and T-cell immunity for chronic hepatitis B functional cure. Currently in Phase 2 ENSURE and BRII-179-002 studies.
- BRII-296 Long-acting therapy in development for postpartum depression (PPD) and major depressive disorder (MDD) with potential to change the paradigm of patient care by helping avoid hospitalization and preserve mother-infant bonding.
- BRII-732 Therapeutic designed for once-weekly oral dosing for HIV-infected patients to improve quality of life. Currently subject to FDA clinical hold.
- BRII-778 Therapeutic designed for once-weekly oral dosing for HIV-infected patients.
- BRII-636 (OMNIvance) Intravenous ultra-broad-spectrum beta-lactamase inhibitor for the treatment of extended spectrum beta-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae, developed with Qpex Biopharma.
- BRII-672 (ORAvance) Oral ultra-broad-spectrum beta-lactamase inhibitor for treatment of MDR gram-negative bacterial infections, developed with Qpex Biopharma.
- BRII-693 (QPX-9003) Next generation synthetic polymyxin for treatment of MDR infections caused by Pseudomonas aeruginosa and Acinetobacter baumannii. Brii Biosciences acquired global exclusive rights from Qpex Biopharma in June 2023.
- BRII-877 (VIR-3434) Broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen for which Brii Bio licensed exclusive rights in Greater China from Vir Biotechnology (option exercised July 2022). Received CDE Breakthrough Therapy Designation from China's Center for Drug Evaluation.
Quantifiable outcome
- Strong cash position of US$276.1 million as of December 31, 2025
- +1 more outcomes
Companies that use Brii Biosciences
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Brii Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Brii Biosciences partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- China Resources Pharmaceutical Commercial GroupcoreStrategic partnership to advance commercialization of long-acting COVID-19 neutralizing antibody therapy amubarvimab/romlusevimab combination in China.
- SinopharmcoreStrategic partnership for commercialization of long-acting COVID-19 neutralizing antibody therapy amubarvimab/romlusevimab combination in China.
- Columbia UniversityminorBrii Bio provided funding to support COVID-19 and coronavirus research led by Dr. David Ho at the Aaron Diamond AIDS Research Center and other Columbia laboratories. Unrestricted grant for creating novel collaboration frameworks.
- Qpex BiopharmacoreMulti-product collaboration to develop and commercialize three antibiotic products in China for treatment of highly resistant gram-negative pathogens including carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
- Artizan BiosciencesminorCollaboration to advance three projects from Artizan's product portfolio using their IgA-SEQ technology platform to identify pro-inflammatory and pathogenic bacteria in the gut.
- VBI VaccinescoreJoint development of BRII-179 (VBI-2601), a novel HBV immunotherapeutic candidate for chronic hepatitis B infection. Brii Bio leads and funds the Phase 1b/2a clinical study in Greater China.
- WuXi Biologics (药明生物)coreExclusive discovery research collaboration for novel bispecific antibody immunotherapeutics. Brii Bio licensed WuXi's WuXiBody bispecific antibody platform for discovering, developing, and manufacturing bispecific antibodies in China.
- Vir BiotechnologycoreVir Biotechnology granted Brii Bio exclusive rights to develop and commercialize up to four infectious disease drug candidates in Greater China. The partnership includes VIR-2218 (BRII-835), an siRNA therapeutic for HBV, and other pipeline candidates.
- Alibaba Health (阿里健康)coreDigital health partnership to explore innovative approaches for clinical research optimization and commercialization, leveraging Alibaba's digital platform and medical AI capabilities to improve patient engagement and drug development efficiency.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Brii Biosciences competitors and assessment
Company assessmentDirect peers
- Zai Lab: NASDAQ/HKEX-listed Chinese biopharma licensing and developing innovative therapies for Greater China; same bridge-company strategy and comparable therapeutic focus areas including infectious disease and oncology.
- VBI Vaccines: Former co-developer of BRII-179 (VBI-2601) HBV immunotherapeutic; Brii Bio recently acquired full IP rights from VBI. Closely comparable in the HBV therapeutic vaccine space and pipeline stage.
- Arbutus Biopharma: Clinical-stage biopharma developing RNAi therapeutics for chronic hepatitis B; comparable mechanism (siRNA), target indication (HBV functional cure), and pipeline stage to Brii Bio's BRII-835 program.
- Vir Biotechnology: Direct peer and counterparty licensor — both companies co-develop siRNA (elebsiran/VIR-2218) and broadly neutralizing mAb (VIR-3434/BRII-877) therapeutics for chronic hepatitis B. Identical scientific platforms, shared pipeline assets, and ongoing arbitration create direct comparability.
- Everest Medicines: Hong Kong-listed Chinese biopharma using a similar 'bridge' model to in-license and develop global innovative therapies for the China market. Highly comparable business model, geography focus, and infectious disease/CNS pipeline profile.
Broad incumbents
- Roche: Global biopharma with established neuroscience and infectious disease franchises; Rogers Luo previously led Roche's China oncology business. Broad incumbent with overlapping therapy area ambitions in China.
- Gilead Sciences: Major incumbent biopharmaceutical company with deep infectious disease (HIV, HBV, COVID) and antiviral portfolio. Multiple Brii Bio leaders (Rogers Luo, Lianhong Xu, Lijie Zhong) came from Gilead, signaling overlapping therapeutic strategy and culture.
- GlaxoSmithKline (GSK): Global biopharma with strong HIV and infectious disease franchise. CEO Zhi Hong, CMO Li Yan, and SVP John Kraus came from GSK; comparable therapeutic areas (HIV, HBV, neuroscience) and talent pool overlap.
Others
- WuXi Biologics: Strategic platform partner providing the WuXiBody bispecific antibody discovery platform to Brii Bio. As a CRO/CDMO and platform provider, WuXi is an enabling peer rather than direct competitor but is closely tied to Brii Bio's discovery capabilities.
Regional players
- Innovent Biologics: Leading Chinese biopharmaceutical company developing innovative biologics including oncology and infectious disease therapeutics; comparable HKEX-listed Chinese biotech with similar innovative drug focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Brii Biosciences social profiles
Digital presenceBrii Biosciences compliance and trust
Trust signalCompliance1 record
Brii Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brii Biosciences leadership team
Management profileNumber of profiles
Profiles13 records
Brii Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brii Biosciences M&A and investment
M&A and investmentM&A
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brii Biosciences
What does Brii Biosciences do?
Brii Biosciences is a multi-national biopharmaceutical company that develops, licenses, and commercializes innovative therapeutic candidates for infectious diseases (chronic hepatitis B, HIV, COVID-19), CNS disorders (postpartum depression, major depressive disorder), and multi-drug resistant bacterial infections, primarily for the Greater China market. The company functions as a bridge between global pharmaceutical innovation (via partnerships with Vir Biotechnology, VBI Vaccines, WuXi Biologics, Qpex Biopharma) and Chinese patients, leveraging its licensed platform technologies (siRNA ESC+, monoclonal antibodies, bispecific antibodies) and partnerships with Sinopharm and China Resources Pharmaceutical Commercial Group for commercialization.
Is Brii Biosciences a public or private company?
Brii Biosciences is a public company. It is classified as public and is currently operating.
When was Brii Biosciences founded?
Brii Biosciences was founded in 2018. It employs 51 to 100 people.
Where is Brii Biosciences based?
Brii Biosciences is headquartered in Beijing, China, in the Asia region.
How does Brii Biosciences make money?
Three revenue lines are on record. Licensing Agreements are the primary driver. The others are product Sales and strategic Partnerships.
Who are Brii Biosciences's main competitors?
Direct peers on record are Zai Lab, VBI Vaccines, Arbutus Biopharma, Vir Biotechnology and Everest Medicines. Broad incumbents are Roche, Gilead Sciences and GlaxoSmithKline (GSK). WuXi Biologics is listed as an others. Innovent Biologics is listed as a regional player.
Does Brii Biosciences have an API?
No public API is recorded for Brii Biosciences.
What industry is Brii Biosciences in?
Brii Biosciences's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAKAGAH, Tuberculosis & Mycobacterial Diseases. Its NAICS code is 325414 and its SIC code is 2836.